⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064183 | 0.80 | MAPK1 (0.42) | — | |
| SCHEMBL3713009 | 0.71 | — | — | |
| SCHEMBL193797 | 0.71 | — | — | |
| SCHEMBL5584028 | 0.71 | AHR (0.30) | — | |
| SCHEMBL38194 | 0.71 | — | — | |
| SCHEMBL5582336 | 0.69 | — | — | |
| SCHEMBL5344839 | 0.67 | CYP1A2 (0.34) | — | |
| SCHEMBL5581272 | 0.67 | — | — | |
| SCHEMBL263568 | 0.67 | — | — | |
| SCHEMBL2992585 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| CN-116041220-B | Preparation method of aryl substituted amide compound | 浙江工业大学 | 2024-05-03 | — | — | CN | claimed |
| CN-116354799-A | Preparation method of dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-116262690-A | Synthesis method of (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) methanone | 苏州小栗医药科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-116262691-A | (5-bromo-2-chlorophenyl) (4-fluorophenyl) methanone | 苏州小栗医药科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116041220-A | Preparation method of aryl substituted amide compound | 浙江工业大学 | 2023-05-02 | — | — | CN | claimed |
| CN-115867538-A | Preparation of highly pure amorphous dapagliflozin | 新梅斯托克公司 | 2023-03-28 | — | — | CN | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| CN-217248929-U | (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) ketone preparation facilities | 河南科来福化工有限公司 | 2022-08-23 | — | — | CN | claimed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| CN-101316853-A | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-12-03 | — | — | CN | claimed |
| EP-1910385-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| EP-0549600-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1993-07-07 | — | — | EP | claimed |
| WO-1992005163-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1992-04-02 | — | — | WO | claimed |